DNA SEQUENCING

描述（由申请人提供）：综合癌症研究所内的许多实验室 中心（CCC）需要自动化，高通量的DNA测序为他们的研究计划。 因此，合作理事会成员必须能够利用一种设施，以具有成本效益的方式及时提供DNA序列分析。 我们建议将现有的DNA测序核心服务扩展到癌症中心成员。 该设施的具体目标是：1。为癌症中心成员提供DNA模板制备、引物设计和循环测序方法的技术支持和培训;提供先进的自动化DNA测序能力，包括提供和维护使用平板凝胶和毛细管电泳系统的专用应用生物系统DNA测序仪;以及3.为序列编辑和分析提供技术支持。现有的DNA测序核心已经运行了15年，在过去5年中产生了超过3400万个碱基对的主要序列，为300多个个人用户提供服务。 电流通过- 该设施每年可进行超过18，000次测序反应。 虽然最初成立和部分资助UAB艾滋病研究中心，CCC成员约占该设施的使用率的79%。 在2003年使用该设施的117名经同行评审、独立资助的主要研究者中，64名是CCC成员。 目前，该设施的资金主要来自退款，每个测序反应需要10美元的费用来支付运营成本。 要求癌症中心提供的支持将使我们能够降低每个反应的成本，从而使CCC研究人员更负担得起自动测序。

DESCRIPTION (provided by applicant): Numerous laboratories within the Comprehensive Cancer Center (CCC) require automated, high through-put DNA sequencing for their research programs. It is thus imperative that CCC members have access to a facility that provides DNA sequence analysis in a cost-effective, timely manner. We propose to expand the services of an existing DNA Sequencing Core to Cancer Center members. The specific aims of this facility are: 1. To provide technical support and training to Cancer Center members in DNA template preparation, primer design, and cycle sequencing methodologies; 2. To provide state-of-the-art automated DNA sequencing capabilities through the availability and maintenance of dedicated Applied Biosystems DNA Sequencers using both slab gel and capillary electrophoresis systems; and 3. To provide technical support for sequence editing and analysis. The existing DNA Sequencing Core has been in operation for 15 years generating over 34 million base pairs of primary sequence in the past 5 years serving over 300 individual users. The current through- put of the facility is over 18,000 sequencing reactions per year. Although originally established and partially funded by the UAB Center for AIDS Research, CCC members are accounting for roughly 79% of this facility's usage. Of 117 peer-reviewed, independently funded Principal Investigators who used this facility in 2003, 64 were CCC members. At the present time, the facility is mostly funded through chargebacks, necessitating a fee of $10 per sequencing reaction to meet operating costs. The requested support from the Cancer Center would allow us to reduce these costs per reaction, thus making automated sequencing more affordable for CCC investigators.